Sinopharm Group Co. Ltd. (SHTDY)
USD 11.65
(2.92%)
USD 11.65
(2.92%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 596.56 Billion CNY | 8.05% |
| 2022 | 552.14 Billion CNY | 5.97% |
| 2021 | 521.05 Billion CNY | 14.16% |
| 2020 | 456.41 Billion CNY | 7.32% |
| 2019 | 425.27 Billion CNY | 23.44% |
| 2018 | 344.52 Billion CNY | 24.36% |
| 2017 | 277.02 Billion CNY | 7.33% |
| 2016 | 258.11 Billion CNY | 13.69% |
| 2015 | 227.02 Billion CNY | 13.44% |
| 2014 | 200.13 Billion CNY | 19.94% |
| 2013 | 166.86 Billion CNY | 22.89% |
| 2012 | 135.78 Billion CNY | 32.83% |
| 2011 | 102.22 Billion CNY | 47.65% |
| 2010 | 69.23 Billion CNY | 47.16% |
| 2009 | 47.04 Billion CNY | 23.2% |
| 2008 | 38.18 Billion CNY | 22.75% |
| 2007 | 31.11 Billion CNY | 31.06% |
| 2006 | 23.73 Billion CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 147.26 Billion CNY | -2.25% |
| 2024 Q2 | 147.46 Billion CNY | 0.13% |
| 2023 Q3 | 144.96 Billion CNY | -6.73% |
| 2023 FY | 596.56 Billion CNY | 8.05% |
| 2023 Q1 | 145.51 Billion CNY | -0.17% |
| 2023 Q4 | 150.64 Billion CNY | 3.92% |
| 2023 Q2 | 155.43 Billion CNY | 6.81% |
| 2022 Q4 | 145.76 Billion CNY | 0.59% |
| 2022 Q1 | 127.59 Billion CNY | -8.71% |
| 2022 FY | 552.14 Billion CNY | 5.97% |
| 2022 Q2 | 133.87 Billion CNY | 4.92% |
| 2022 Q3 | 144.9 Billion CNY | 8.24% |
| 2021 FY | 521.05 Billion CNY | 14.16% |
| 2021 Q3 | 132.16 Billion CNY | 2.57% |
| 2021 Q2 | 128.85 Billion CNY | 7.14% |
| 2021 Q4 | 139.76 Billion CNY | 5.75% |
| 2021 Q1 | 120.26 Billion CNY | -6.63% |
| 2020 Q2 | 109.36 Billion CNY | 15.85% |
| 2020 Q4 | 128.8 Billion CNY | 4.0% |
| 2020 Q3 | 123.84 Billion CNY | 13.24% |
| 2020 Q1 | 94.39 Billion CNY | -16.15% |
| 2020 FY | 456.41 Billion CNY | 7.32% |
| 2019 Q3 | 111.02 Billion CNY | 4.26% |
| 2019 FY | 425.27 Billion CNY | 23.44% |
| 2019 Q1 | 95.17 Billion CNY | 1.57% |
| 2019 Q2 | 106.48 Billion CNY | 11.88% |
| 2019 Q4 | 112.58 Billion CNY | 1.41% |
| 2018 Q2 | 84.52 Billion CNY | 7.07% |
| 2018 FY | 344.52 Billion CNY | 24.36% |
| 2018 Q1 | 78.94 Billion CNY | -7.44% |
| 2018 Q3 | 87.34 Billion CNY | 3.33% |
| 2018 Q4 | 93.7 Billion CNY | 7.28% |
| 2017 FY | 277.02 Billion CNY | 7.33% |
| 2017 Q3 | 85.29 Billion CNY | 23.82% |
| 2017 Q4 | 85.29 Billion CNY | 0.0% |
| 2017 Q1 | 68.88 Billion CNY | 4.7% |
| 2017 Q2 | 68.88 Billion CNY | 0.0% |
| 2016 Q1 | 62.58 Billion CNY | 6.42% |
| 2016 Q4 | 65.79 Billion CNY | 0.0% |
| 2016 Q3 | 65.79 Billion CNY | 2.45% |
| 2016 Q2 | 64.21 Billion CNY | 2.62% |
| 2016 FY | 258.11 Billion CNY | 13.69% |
| 2015 Q2 | 55.9 Billion CNY | 1.37% |
| 2015 Q3 | 58.8 Billion CNY | 5.19% |
| 2015 Q4 | 58.8 Billion CNY | 0.0% |
| 2015 FY | 227.02 Billion CNY | 13.44% |
| 2015 Q1 | 55.15 Billion CNY | 4.76% |
| 2014 FY | 200.13 Billion CNY | 19.94% |
| 2014 Q4 | 52.64 Billion CNY | 0.0% |
| 2014 Q3 | 52.64 Billion CNY | 11.03% |
| 2014 Q2 | 47.41 Billion CNY | 0.0% |
| 2014 Q1 | 47.41 Billion CNY | 9.26% |
| 2013 Q1 | 40.03 Billion CNY | 0.0% |
| 2013 FY | 166.86 Billion CNY | 22.89% |
| 2013 Q2 | 40.03 Billion CNY | 0.0% |
| 2013 Q4 | 43.39 Billion CNY | 0.0% |
| 2013 Q3 | 43.39 Billion CNY | 8.41% |
| 2012 FY | 135.78 Billion CNY | 32.83% |
| 2011 FY | 102.22 Billion CNY | 47.65% |
| 2010 FY | 69.23 Billion CNY | 47.16% |
| 2009 FY | 47.04 Billion CNY | 23.2% |
| 2008 FY | 38.18 Billion CNY | 22.75% |
| 2007 FY | 31.11 Billion CNY | 31.06% |
| 2006 FY | 23.73 Billion CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| China Medicine Corporation | 64.75 Million USD | -921228.472% |
| DH Enchantment Inc. | 686.00 USD | -86963493340.233% |
| Exlites Holdings International, Inc. | 18.74 Thousand USD | -3183402061.153% |
| Itonis, Inc. | 1801.00 USD | -33124351093.781% |
| One Step Vending Corp. | - USD | -Infinity% |
| MediPal Holdings Corporation | 23.51 Billion USD | -2437.24% |
| PD-Rx Pharmaceuticals, Inc. | 21.27 Million USD | -2804433.615% |
| Pharmagen, Inc. | 4813.05 USD | -12394834048.825% |
| Suzuken Co., Ltd. | 15.76 Billion USD | -3683.525% |